PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 42691830

Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.

Hiroto Hatano·Tatsuya Yoshida·Ryoko Inaba Higashiyama·Masayuki Shirasawa·Yoshiro Nakahara·Katsuhiko Naoki·Hiroshi Nokihara·Kentaro Gosho·Yuji Uehara·Yukio Hosomi·Ayu Kiritani·Hiroshi Wakui·Yuki Shinno·Yusuke Okuma·Hidehito Horinouchi·Noboru Yamamoto·Yasushi Goto
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) exon 19 deletion subtypes may be associated with differential survival outcomes following EGFR-tyrosine kinase inhibitor treatment. However, evidence remains scarce, particularly regarding osimertinib, and the underlying biological mechanisms are poorly understood. We aimed to compare survival outcomes among EGFR exon 19 deletion subtypes in patients with non-small cell lung cancer (NSCLC) treated with osimertinib. METHODS: In this multicenter retrospective study, patients with NSCLC were stratified according to exon 19 deletion subtypes. Whole-exome sequencing data from the American Association for Cancer Research Genomics Evidence Neoplasia Information Exchange registry and Memorial Sloan Kettering Clinicogenomic Harmonized Oncologic Real-World Dataset were analyzed to investigate co-occurring genomic alterations. RESULTS: Overall, 111 patients with advanced EGFR exon 19 deletion-positive NSCLC were analyzed and 86.5% received osimertinib as first-line therapy. Patients with non-E746_A750del (n&#xa0;=&#xa0;25) had shorter progression-free survival (PFS) than those with E746_A750del (n&#xa0;=&#xa0;86) (median: 14.3 vs. 20.6&#xa0;months; p&#xa0;<&#xa0;0.05). Among non-E746_A750del subtypes, L747_A750delinsP (n&#xa0;=&#xa0;4) had a particularly poor prognosis, with significantly worse survival than those with E746_A750del (median PFS: 3.5 vs. 20.6&#xa0;months; p&#xa0;<&#xa0;0.001, and median overall survival: 11.8 vs. 48.5&#xa0;months; p&#xa0;<&#xa0;0.001). In public database analyses, non-E746_A750del had a higher rate of RBM10 co-mutations, whereas L747_A750delinsP was characterized by frequent CDKN2A/B homozygous deletions and MYC amplifications. CONCLUSIONS: Non-E746_A750del was associated with poorer outcomes, with L747_A750delinsP potentially being a high-risk subtype. Differences in co-occurring genomic alterations may contribute to the prognostic heterogeneity among exon 19 deletion subtypes.

Explore related subjects

HumansAcrylamidesAniline CompoundsPyrimidinesLung NeoplasmsFemaleIndolesCarcinoma, Non-Small-Cell LungErbB ReceptorsExonsRetrospective StudiesMaleSequence DeletionAgedMiddle AgedProtein Kinase InhibitorsTreatment OutcomeAged, 80 and overAntineoplastic AgentsGenomicsAdultPrognosisEpidermal growth factor receptorExon 19 deletionOsimertinibRNA binding motif 10Journal ArticleMulticenter Study

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hiroto Hatano, Tatsuya Yoshida, Ryoko Inaba Higashiyama, Masayuki Shirasawa, Yoshiro Nakahara, Katsuhiko Naoki, Hiroshi Nokihara, Kentaro Gosho, Yuji Uehara, Yukio Hosomi, Ayu Kiritani, Hiroshi Wakui, Yuki Shinno, Yusuke Okuma, Hidehito Horinouchi, Noboru Yamamoto, Yasushi Goto. 2026-08-31. Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.. https://doi.org/10.1016/j.lungcan.2026.109604

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗
PubMed2027

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗
PubMed2027

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗